Evidence map›Paper›PMID 37904704›Full record

ArticleImmunity, inflammation and disease2023

Differential expression of Type I interferon and inflammatory genes in SARS-CoV-2-infected patients treated with monoclonal antibodies.

Luca Maddaloni, Letizia Santinelli, Ginevra Bugani, Elio G Cacciola, Alessandro Lazzaro, Chiara M Lofaro, Sara Caiazzo, Federica Frasca, Matteo Fracella, Camilla Ajassa and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Luca MaddaloniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Letizia SantinelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Ginevra BuganiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Elio G CacciolaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Alessandro LazzaroDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Chiara M LofaroDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Sara CaiazzoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Federica FrascaVirology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Matteo FracellaVirology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Camilla AjassaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Cristiana LeanzaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Anna NapoliLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Lilia CintiLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Aurelia GaetaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Guido AntonelliVirology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giancarlo CeccarelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.ORCID 0000-0001-5921-3180
Claudio M MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Carolina ScagnolariVirology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-1044-1478
Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionConsidering the reported efficacy of monoclonal antibodies (mAbs) directed against the Spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in reducing disease severity, the aim of this study was to investigate the innate immune response before and after mAbs treatment in 72 vaccinated and 31 unvaccinated SARS-CoV-2 patients.

methodsThe mRNA levels of IFN-I, IFN-related genes and cytokines were evaluated using RT/real-time quantitative PCR.

resultsVaccinated patients showed increased rate of negative SARS-CoV-2 PCR tests on nasopharyngeal swab compared with unvaccinated ones after mAbs treatment (p = .002). Unvaccinated patients had lower IFN-α/ω and higher IFN-related genes (IFNAR1, IFNAR2, IRF9, ISG15, ISG56 and IFI27) and cytokines (IL-6, IL-10 and TGF-β) mRNA levels compared to vaccinated individuals before mAbs (p < .05 for all genes). Increased IFN-α/ω, IFNAR1, IFNAR2 and IRF9 levels were observed in unvaccinated patients after mAbs treatment, while the mRNA expression ISGs and IL-10 were reduced in all patients.

conclusionThese data suggest that anti-S vaccinated patients have increased levels of innate immune genes compared to unvaccinated ones. Also, gene expression changes in IFN genes after mAbs administration are different according to the vaccination status of patients.

Indexed as

COVID-19Interferon Type IAntibodies, MonoclonalCytokinesHumansInterferon-alphaInterleukin-10RNA, MessengerSARS-CoV-2Antibodies, MonoclonalCytokinesInterferon-alphaInterferon Type IInterleukin-10RNA, Messengerinterferon-stimulated genesmonoclonal antibodiesSARS-CoV-2Type I interferons

Identifiers

PMID37904704
PMCPMC10571496
OpenAlexW4387618666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.